Karyopharm Therapeutics Inc (KPTI) - Total Liabilities

Latest as of September 2025: $365.49 Million USD

Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has total liabilities worth $365.49 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Karyopharm Therapeutics Inc (KPTI) cash flow conversion to assess how effectively this company generates cash.

Karyopharm Therapeutics Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how Karyopharm Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check KPTI asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Karyopharm Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Karyopharm Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Etga Group Ltd TA:ETGA	Israel	ILA547.23 Million
Forth Smart Service Public Company Limited BK:FSMART	Thailand	฿1.91 Billion
Sermsang Power Corporation Public Company Limited BK:SSP	Thailand	฿17.53 Billion
Ordinary Fully Paid Deferred Settlement AU:BTRDA	Australia	AU$41.10 Million
Quercus TFI SA WAR:QRS	Poland	zł107.90 Million
Intellego Technologies AB ST:INT	Sweden	Skr203.26 Million
TIZIANA LIFE SCIENCES LTD F:0RP	Germany	€7.35 Million
SKP Resources Bhd KLSE:7155	Malaysia	RM398.96 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Karyopharm Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KPTI company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.03	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.36	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	3.80	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Karyopharm Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Karyopharm Therapeutics Inc (2011–2025)

The table below shows the annual total liabilities of Karyopharm Therapeutics Inc from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	$401.34 Million	+14.53%
2024-12-31	$350.44 Million	-6.96%
2023-12-31	$376.64 Million	+0.48%
2022-12-31	$374.83 Million	-2.64%
2021-12-31	$384.98 Million	+46.66%
2020-12-31	$262.50 Million	+7.06%
2019-12-31	$245.19 Million	+55.16%
2018-12-31	$158.02 Million	+210.88%
2017-12-31	$50.83 Million	+180.18%
2016-12-31	$18.14 Million	+6.23%
2015-12-31	$17.08 Million	+26.10%
2014-12-31	$13.54 Million	+311.39%
2013-12-31	$3.29 Million	-88.72%
2012-12-31	$29.19 Million	+46.86%
2011-12-31	$19.88 Million	--

About Karyopharm Therapeutics Inc

NASDAQ:KPTI USA Biotechnology

Market Cap

$160.59 Million

Market Cap Rank

#17460 Global

#3927 in USA

Share Price

$8.77

Change (1 day)

+5.54%

52-Week Range

$3.77 - $10.09

All Time High

$27.72